Apr 24, 2025
Discover Your Radiation Toxicity Risk with PROSTOX

What if you could predict radiation side effects before treatment begins? By analyzing your unique genetics, you can make smarter, more informed decisions to avoid side effects and safeguard your quality of life for years to come.
Dr. Weidhaas, a co-founder of MiraDx and professor at UCLA, leads translation research in radiation oncology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology, and treatment response. She co-founded MiraDx and MiraKind to empower individuals with meaningful health information. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center and previously served as Chief of the Breast Cancer Radiation Service at Yale Cancer Center. She completed an MSM at Stanford University during a sabbatical at Yale. She moved to UCLA as Professor and Division Head, Translational Research, in 2014. Her dual role as a clinician and researcher applies genetic breakthroughs to patient benefit. She currently resides in the LA area with her husband and three children.